SupraMolecular BioVectors (SMBV) improve antisense inhibition of erbB-2 expression

Allal, Ben; Sixou, Sophie; Kravtzoff, Roger; Soulet, Nadine; Soula, G; Favre, Gilles

doi:10.1038/bjc.1998.238

Cited by 11 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The in- hibitory effect on the expression of erbB-2 was maximal 48 h after treatment, and inhibition was greatest at the concentration of 10 ÌM erbB-2-AS (data not shown). Although similar strategies have already been reported with a vector system in breast cancer [20], in that report, the efficiency of antisense inhibition of erbB-2 was certainly improved and the effect was shown to be due to the sensitivity of erbB-2 to nucleases. The inhibitory effects of Funato/Kozawa/Fujimaki/Miura an anti-erbB-2 ribozyme, as well as an antisense effect, have been demonstrated in ovarian cancer [21].…”

Section: Discussionmentioning

confidence: 88%

Increased Sensitivity to Cisplatin in Gastric Cancer by Antisense Inhibition of the HER-2/neu (c-erbB-2) Gene

Funato

Kozawa²,

Fujimaki³

et al. 2001

Chemotherapy

View full text Add to dashboard Cite

Background: The c-erbB-2 oncogene encodes a transmembrane tyrosine kinase receptor and its abnormal expression may be related to the prognosis of gastric cancer. Gastric cancer is relatively resistant to various drugs, including cisplatin. Cisplatin is widely used in cancer chemotherapy, but the mechanisms of drug resistance are not yet known. Methods: We used the human gastric cancer cell lines MKN-7 and KATO-III, which express the c-erbB-2 oncogene, as a model for relative resistance to cisplatin. We investigated whether inhibition with antisense oligonucleotides against c-erbB-2 increased the sensitivity of MKN-7 and KATO-III cells to cisplatin. Results: Antisense oligonucleotides for c-erbB-2 inhibited the expression of c-erbB-2 mRNA and protein and increased sensitivity to cisplatin, but not to other drugs, in MKN-7 and KATO-III cells. Cell growth was also inhibited by c-erbB-2 antisense oligonucleotides but not sense oligonucleotides. Conclusions: These findings indicate that c-erbB-2 expression in gastric cancer is one of the factors related to cisplatin sensitivity, and that anti-c-erbB-2 antisense oligonucleotides induced increased sensitivity to cisplatin.

show abstract

Section: Discussionmentioning

confidence: 88%

Increased Sensitivity to Cisplatin in Gastric Cancer by Antisense Inhibition of the HER-2/neu (c-erbB-2) Gene

Funato

Kozawa²,

Fujimaki³

et al. 2001

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…54 Next to proteins, also antisense oligonucleotides have been encapsulated in SMBVs. 197 Lipid-enveloped dextran NPs were additionally investigated as a nanotheranostic platform by Erten and coworkers. The dextran nanogel matrix, loaded with doxorubicin, was constructed around an iron oxide core as an MRI contrast agent.…”

Section: Lipid-coated Hydrogel Nanoparticles In Drug Deliverymentioning

confidence: 99%

Merging the best of both worlds: hybrid lipid-enveloped matrix nanocomposites in drug delivery

et al. 2014

View full text Add to dashboard Cite

The advent of nanotechnology has revolutionized drug delivery in terms of improving drug efficacy and safety. Both polymer-based and lipid-based drug-loaded nanocarriers have demonstrated clinical benefit to date. However, to address the multifaceted drug delivery challenges ahead and further expand the spectrum of therapeutic applications, hybrid lipid-polymer nanocomposites have been designed to merge the beneficial features of both polymeric drug delivery systems and liposomes in a single nanocarrier. This review focuses on different classes of nanohybrids characterized by a drug-loaded polymeric matrix core enclosed in a lipid shell. Various nanoengineering approaches to obtain lipid-polymer nanocomposites with a core-shell nanoarchitecture will be discussed as well as their predominant applications in drug delivery.

show abstract

“…Antisense ODN -mediated down -regulation of HER -2 expression has been the subject of several studies, performed on one, 33,34 two, 26,35 three 25,36 or more 24,37 human breast cancer cell lines. With one exception, 25 the HER -2 -overexpressing cell line SK -BR -3 has been used in all studies and is compared most often to MCF7 cells, which do not have an amplified HER -2 gene and possess only a basal level of its protein product.…”

Section: Discussionmentioning

confidence: 99%

Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer

et al. 2001

View full text Add to dashboard Cite

Poor response to chemotherapy in patients with breast cancer is often associated with overexpression of HER -2 / neu. Interference with HER -2 mRNA translation by means of antisense oligonucleotides might improve the efficacy of chemotherapy. To test this hypothesis, eight breast cancer cell lines and a normal human fibroblast cell line were examined for their level of HER -2 expression, their sensitivity to phosphorothioate antisense oligonucleotides ( AS HER -2 ODN ), and to various chemotherapeutic agents, and the combination of the two. No correlation was found between the intrinsic HER -2 level and either the sensitivity to a particular chemotherapeutic agent alone, or the amount of growth inhibition observed with a specific AS HER -2 ODN concentration. Although sequence specificity and extent of AS HER -2 ODN inhibition of HER -2 synthesis were somewhat higher in the HER -2 overexpressing MDA -MB -453 and SK -BR -3 cells, we found that antisense treatment significantly sensitized all of the breast cancer cells, even MDA -MB -231 and MDA -MB -435 cells, with approximately basal levels of HER -2, to various chemotherapeutic agents. In addition, the combination of AS HER -2 ODN and taxol was shown to synergistically induce apoptosis in MDA -MB -435. These results demonstrate that overexpression of HER -2 would not be a prerequisite for the effective use of AS HER -2 ODN as a combination treatment modality for breast cancer and suggest that the use of AS HER -2 ODN, as part of a combination treatment modality, need not be limited to breast tumors that display elevated levels of HER -2. Cancer Gene Therapy ( 2001 ) 8, 728 -739

show abstract

SupraMolecular BioVectors (SMBV) improve antisense inhibition of erbB-2 expression

Cited by 11 publications

References 26 publications

Increased Sensitivity to Cisplatin in Gastric Cancer by Antisense Inhibition of the HER-2/neu (c-erbB-2) Gene

Increased Sensitivity to Cisplatin in Gastric Cancer by Antisense Inhibition of the HER-2/neu (c-erbB-2) Gene

Merging the best of both worlds: hybrid lipid-enveloped matrix nanocomposites in drug delivery

Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer

Contact Info

Product

Resources

About